“Ineffective and risky,” says RFK Jr. about mRNA vaccines.
But experts warn: cutting mRNA funding could leave Americans more dependent on foreign breakthroughs—and possibly more vulnerable.
Health and Human Services Secretary Robert F. Kennedy Jr. announced this week that his department will halt all funding for mRNA vaccine development, abruptly shutting down 22 federally-backed projects worth nearly $500 million.
In a video posted on X (formerly Twitter), Kennedy said that messenger RNA (mRNA) technology, used in the most common COVID-19 vaccines in the U.S., is “ineffective” and “dangerous.” According to him, the decision to end funding comes from a growing belief that the risks outweigh the benefits.
The decision has rattled scientists, raised confusion among patients, and deepened an already chaotic national conversation about vaccines, public health policy, and the future of pandemic response.
What Is Being Shut Down?
The target of this sweeping cut is the Biomedical Advanced Research and Development Authority (BARDA)—a federal agency under the HHS that supports the development of medical countermeasures for public health threats, from pandemics to bioterrorism.
The canceled projects span a wide range of applications, from next-generation COVID-19 boosters to experimental treatments for cancer and autoimmune diseases, all using mRNA platforms. This technology was at the core of the Pfizer-BioNTech and Moderna vaccines during the height of the pandemic.
Is mRNA Really “Ineffective”?
Let’s not sugarcoat it—Kennedy’s claim that mRNA vaccines are “ineffective” flies in the face of current science.
“This technology played a vital role in our pandemic response and continues to show promise for treating serious diseases,” said Jeff Coller, Bloomberg Distinguished Professor of RNA Biology at Johns Hopkins University. “While other countries move ahead with these proven therapies, we risk falling behind.”
The FDA and CDC still stand by mRNA vaccines as safe and effective. The World Health Organization also endorses mRNA technology.
So where is Kennedy getting his evidence from?
That’s unclear. His statements cite no peer-reviewed studies. What they do reflect, however, is his long-standing opposition to vaccination mandates and skepticism of pharmaceutical companies.
How Do mRNA Vaccines Actually Work?
To understand what we’re about to lose, it helps to grasp what mRNA does. And no, it doesn’t alter your DNA or turn you into a lizard.
Messenger RNA is like a text message to your immune system. It tells your body’s cells to make a harmless piece of the virus—specifically the spike protein on the surface of SARS-CoV-2, the virus that causes COVID-19. Your immune system spots the fake protein and starts preparing antibodies.
Because the vaccine contains only a genetic instruction—not the virus itself—you can’t get COVID-19 from the shot, and you don’t need egg-based ingredients (a relief for allergy sufferers).
The technology allowed scientists to develop vaccines within months, not years. And its potential goes far beyond COVID. mRNA is being explored for cancer treatment, HIV prevention, and even individualized therapies.
Kennedy just unplugged it.
What Does This Mean for COVID Vaccines This Fall?
In short: things are murky.
During his first few months in office, Kennedy fired the entire Advisory Committee on Immunization Practices (ACIP)—the group of experts responsible for recommending vaccine schedules. He replaced them with eight new members, none of whom made any recommendation on COVID-19 for the upcoming season.
The CDC website confirms the committee won’t meet again until “September or October,” leaving physicians in limbo.
Further, Kennedy announced back in May that COVID-19 vaccines will no longer be recommended for healthy children and pregnant women—a decision made without the usual scientific review process. This move breaks sharply from the positions of major medical bodies, including:
- The American College of Obstetricians and Gynecologists (ACOG)
- The American Academy of Pediatrics (AAP)
Both groups condemned the decision as dangerous and politically driven.
Who Can Still Get a COVID Shot?
Under the new guidelines, only adults over 65 and people with pre-existing health conditions will be advised to receive the vaccine.
This leaves a large segment of the population—including health care workers, parents of immunocompromised children, and people under 65—in an awkward spot. If they want to get vaccinated, they’ll have to find a doctor who’s still willing to administer it off-guideline.
That could mean fewer doses are ordered, distributed, or covered by insurance.
Will Insurance Still Cover COVID Vaccines?
So far, insurance companies are trying to stay the course.
A KFF poll published August 1 shows 40% of U.S. adults plan to get a COVID-19 shot if it’s available. But 62% of them worry that their insurance won’t cover it under the new administration’s policies.
Industry reps say they’ll continue to follow federal requirements—but that’s where things get tricky. If the CDC and ACIP aren’t recommending vaccines, insurers technically aren’t required to pay for them.
“Health plans continue to follow federal rules related to vaccine coverage,” said Tina Stow, spokesperson for AHIP, which represents health insurance providers. “We’re committed to supporting access to critical preventive services.”
But what counts as “critical” now seems up for debate.
Some large employers may continue to cover FDA-approved vaccines, regardless of ACIP’s silence. That means your access could depend on your job—or your doctor’s personal views.
So… Now What?
If you’re under 65, healthy, and not on a government-recommended list, getting a COVID-19 vaccine this fall might be more difficult—but not impossible.
Doctors may still choose to offer it. Pharmacies may still stock it. And companies may still cover it. But there’s a growing risk that the infrastructure supporting wide-scale vaccination is starting to crumble.
More troublingly, mRNA-based research for other diseases may now face delays, or move overseas entirely, as the U.S. backs away from a field it once led.
Kennedy’s critics call it an ideologically-driven overreaction. His supporters call it a long-overdue correction.
But regardless of where you fall on the spectrum, one fact is becoming clear: the future of vaccine innovation in America just hit a hard pause.
Sources:
